215 related articles for article (PubMed ID: 16143028)
1. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
Kim KH; Suh KS; Kang DW; Kang DY
Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
[TBL] [Abstract][Full Text] [Related]
2. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
3. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
[TBL] [Abstract][Full Text] [Related]
4. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma.
Kim HS; Kim JO; Lee DH; Lee HC; Kim HJ; Kim JH; Jang YS; Lee JM; Kim SY; Kim YS
Oncol Rep; 2011 Jun; 25(6):1639-44. PubMed ID: 21431280
[TBL] [Abstract][Full Text] [Related]
8. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
[TBL] [Abstract][Full Text] [Related]
9. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.
Smith RA; Salajegheh A; Weinstein S; Nassiri M; Lam AK
Hum Pathol; 2011 Apr; 42(4):500-6. PubMed ID: 21167555
[TBL] [Abstract][Full Text] [Related]
10. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
Jakubowski M; Hunt JL
Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
[TBL] [Abstract][Full Text] [Related]
12. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
13. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
15. Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change.
Nasr MR; Mukhopadhyay S; Zhang S; Katzenstein AL
Am J Clin Pathol; 2009 Dec; 132(6):906-12. PubMed ID: 19926583
[TBL] [Abstract][Full Text] [Related]
16. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
18. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma.
Trovisco V; Soares P; Soares R; Magalhães J; Sá-Couto P; Sobrinho-Simões M
Hum Pathol; 2005 Jun; 36(6):694-7. PubMed ID: 16021577
[TBL] [Abstract][Full Text] [Related]
19. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.
Jin L; Sebo TJ; Nakamura N; Qian X; Oliveira A; Majerus JA; Johnson MR; Lloyd RV
Diagn Mol Pathol; 2006 Sep; 15(3):136-43. PubMed ID: 16932068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
